Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 in Recurrent or Metastatic Vulvar Cancer
NCT05932212Phase 2Terminated
- Sponsor
- Akeso, Inc.
- Start
- Aug 2023
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in vulvar cancer, sponsored by Akeso, Inc.. Started Aug 2023; status: terminated.
02
Drugs
cadonilimab
03
Conditions
vulvar cancer
Beyond the preview
Go deeper on NCT05932212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932212.